Clinical trials: High-risk Medications
Substance Use, Mental Health Issue
Community Driven Substance Use Recovery for High Opioid Overdose Areas
The main goal of this current study is to develop and optimize methods for increasing access to, uptake of, and engagement in MAT (Medication Assisted Treatment) among communities of color.
- Conditions
- Substance Use, Mental Health Issue, Opioid Use, Medication Assisted Treatment
- Trial name
- IMANI U (NCT05260047)
- Testing
- IMANI, Telehealth MAT, Traditional MAT plus Referral and Linkage
- Where
- 8 sites in United States
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- Yale University
HIV
PrEP Demonstration Project (PRELUDE Study)
Significant increases in HIV diagnoses among gay and other homosexually active men, in Australia and internationally, have been observed since the late 1990s.
- Trial name
- PRELUDE (NCT02206555)
- Testing
- emtricitabine/tenofovir disoproxil fumarate
- Where
- 5 sites in Australia
- Volunteers
- 327 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Adverse Drug Events, Adverse Drug Reactions
The Effect of Medication Review in High-risk Emergency Department Patients
Adverse drug events are unintended and harmful events related to medication use and a leading cause of emergency department visits, unplanned hospital admissions and deaths.
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Medication-related Problems
- Trial name
- NCT02122965
- Testing
- Pharmacist-led medication review
- Where
- 3 sites in Canada
- Volunteers
- 10,805 people
- Sponsor
- University of British Columbia
Older Adults (65 Years and Older), Chronic Kidney Disease (CKD)
Pramipexole and the Risk of Serious Adverse Events
This is a population-based cohort study assessing whether initiation of a higher dose of pramipexole (0.25 or 0.375 mg/day), compared with a lower dose (0.125 mg/day), in older adults with advanced chronic kidney disease (CKD)…
- Trial name
- NCT07382960
- Testing
- Pramipexole
- Where
- Canada
- Volunteers
- 1,100 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
The Patient Cohort of the National Center for Precision Medicine in Leukemia
If for years the treatment strategy of leukemia and related disorders (LRDs, including acute leukemias and predisposition syndromes) has been based solely on whether the patient could receive or not intensive chemotherapy and…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome, Secondary Myelofibrosis in Myeloproliferative Disease
- Trial name
- eTHEMA (NCT05326919)
- Testing
- Biobanking
- Where
- 3 sites in France
- Volunteers
- 3,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Osteosarcoma
Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma
The purpose of this study was to collect information regarding the safety and tolerability of mifamurtide (liposomal muramyl tripeptide phosphatidyl ethanolamine; L-MTP-PE).
- Trial name
- NCT00631631
- Testing
- Mifamurtide (L-MTP-PE)
- Where
- 2 sites in United States
- Volunteers
- 205 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Anaerobic Performance
High-Load Blood Flow Restriction (BFR) Training May Decrease Anaerobic Fatigue in Distance Runners
This study investigates the effects of high-load BFR training on anaerobic performance and fatigue resistance in distance runners.
- Trial name
- BFR-Training (NCT06822595)
- Testing
- Blood flow restriction (BFR) training, Isokinetic training
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Gulhane Training and Research Hospital
Cardiovascular Diseases
Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating Subjects With Elevated Risk for Cardiovascular Disease
The purpose of this study is to determine the effect of pioglitazone, once daily (QD), and atorvastatin combination therapy compared to atorvastatin monotherapy in patients at risk for cardiovascular disease.
- Trial name
- NCT00770575
- Testing
- Pioglitazone and atorvastatin, Atorvastatin
- Volunteers
- 148 people
- Sponsor
- Takeda
High-risk Medications
Testing a Medication Risk Communication and Surveillance Strategy: The EMC2 Trial
This study evaluates the effectiveness of an electronic health record based educational intervention (the EMC2 strategy) to improve patient understanding and use of higher-risk medications.
- Trial name
- NCT02785458
- Testing
- EMC2 Strategy
- Where
- United States
- Volunteers
- 1,005 people
- Sponsor
- Northwestern University
Coronary Artery Disease, Coronary Disease
Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI
This study is a prospective, randomized, open-label, single-center trial designed to compare the 30 month-safety and efficacy between low-dose (5mg/dL) and high-dose (20mg/dL) rosuvastatin treatment for patients with coronary…
- Conditions
- Coronary Artery Disease, Coronary Disease, Cardiovascular Diseases
- Trial name
- ROSUVA-30 (NCT02859480)
- Testing
- Rosuvastatin 5mg, Rosuvastatin 20mg
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Korea University Anam Hospital
Stable Angina, Ischemic Heart Disease Silent
A Randomized Clinical Evaluation of the BioFreedom™ Stent
The purpose of this study is to demonstrate that a BioFreedom™ Drug Coated Stent is non-inferior to a bare metal stent at one year as measured by the composite safety endpoint of cardiovascular death, myocardial infarction and…
- Conditions
- Stable Angina, Ischemic Heart Disease Silent, ST Elevation (STEMI) and Non-ST Elevation (NSTEMI) Myocardial Infarction, In-stent Coronary Artery Restenosis
- Trial name
- Leaders Free (NCT01623180)
- Testing
- Biofreedom™ Drug Coated Stent (DCS), Gazelle™ Bare Metal Coronary Stent (BMS)
- Where
- Switzerland
- Volunteers
- 2,456 people
- Sponsor
- Biosensors Europe SA
Chronic Coronary Syndrome
Drug-Coated Balloon Versus Drug-Eluting Stent for Treatment of De-Novo Coronary Lesions in Patients With High Bleeding Risk-2
A prospective, multi-center, open-label, randomized controlled, and superiority trial. The trial will compare clinical outcomes between discontinuation of antiplatelet agent and continuation of antiplatelet agent in HBR patients…
- Trial name
- DCB-HBR-2 (NCT06742931)
- Testing
- Discontinuation of antiplatelet agent group, Continuation of antiplatelet agent group
- Where
- 18 sites in South Korea
- Volunteers
- 1,200 people
- Sponsor
- Samsung Medical Center
Epilepsy
Assessment of MRI-guided HIFU for Patients With Drug-resistant Focal Epilepsy
The goal of this clinical trial is to assess the feasibility, safety, and tolerance of MRI-guided High-Intensity Focused Ultrasound (HIFU) for the treatment of drug-resistant focal epilepsy in adult patients with MRI-visible…
- Trial name
- EPIFUS (NCT07591350)
- Testing
- MR-guided HIFU thermoablation, EEG, MRI
- Volunteers
- 13 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Epilepsy
Add on Lacosamide Versus High Dose Monotherapy
This is a study to determine whether a combination of low dose lacosamide and levetiracetam is more effective than high dose levetiracetam in patients who have failed low dose levetiracetam.
- Trial name
- NCT01345058
- Testing
- lacosamide, levetiracetam
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Brigham and Women's Hospital
Prostatic Neoplasms, Neoplasm Metastasis
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.
- Conditions
- Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs
- Trial name
- CYCLONE 3 (NCT05288166)
- Testing
- Abemaciclib, Abiraterone, Prednisone or Prednisolone
- Where
- 266 sites in United States, Argentina and 22 more
- Volunteers
- 925 people
- Sponsor
- Eli Lilly and Company
Drug/Agent Toxicity by Tissue/Organ, Pancreatic Cancer
Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more tumor cells.
- Trial name
- NCT00024427
- Testing
- fluorouracil, gemcitabine hydrochloride, triacetyluridine
- Where
- 29 sites in United States, Canada
- Volunteers
- 250 people
- Sponsor
- Wellstat Therapeutics
IgA Nephropathy at High Risk of Developing ESRD
Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD
The TCM-WINE study is a single-center, prospective, double-blind randomized placebo-controlled trial. Based on optimal supportive care, the trial is aiming to assess superiority with regard to renal protection and reduction of…
- Trial name
- TCMWINE (NCT03418779)
- Testing
- The Yi-Qi-Qing-Jie herbal compound, Immunosuppressants, Optimized Supportive Care
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation
Effect of High-intensity Statin With Ezetimibe COmbination theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coronary Intervention With Drug-eluting Stents; the ESCORT Trial
This study sought to evaluate whether ezetimibe combination to high-intensity statin therapy will have more prominent beneficial effect compared to high-intensity statin monotherapy in patients who underwent coronary…
- Trial name
- NCT05782777
- Testing
- ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg), high-intensity statin monotherapy (atoravastatin 40mg)
- Where
- South Korea
- Volunteers
- 4,310 people
- Sponsor
- Yonsei University
Ischemic Stroke, Antiplatelet Effect
Double Randomized and Placebo Controlled Trail of Sanchitongshu Combined Antiplatelet Drug to Prevent Ischemic Stroke
This clinical trail will evaluate the effect of Sanchitongshu combined with antiplatelet drugs (Aspirin or Clopidogrel) in the treatment of high-risk ischemic stroke patients in adults.
- Trial name
- NCT04142151
- Testing
- Sanchitongshu, Aspirin, Clopidogrel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Hypertension
Effectiveness and Tolerability of Tarka® in the Treatment of Hypertensive Patients With High Risk of Developing Diabetes Mellitus
The aim of this post-marketing observational study (PMOS) is to provide data on the effectiveness and tolerability of Tarka in patients with a high risk of developing diabetes mellitus, as prescribed by the physicians in a…
- Trial name
- TARDIA (NCT01079195)
- Where
- 898 sites in Bulgaria, Czechia and 5 more
- Volunteers
- 15,436 people
- Sponsor
- Abbott